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ABSTRACT
Helper-dependent adenoviruses show great promise as gene delivery vectors. However, because they do not
integrate into the host chromosome, transgene expression cannot be maintained indefinitely. To overcome
these limitations, we have inserted an L1 retrotransposon/transgene element into a helper-dependent adeno-
virus to create a novel chimeric gene delivery vector. Efficient adenovirus-mediated delivery of the L1 ele-
ment into cultured human cells results in subsequent retrotransposition and stable integration of the trans-
gene. L1 retrotransposition frequency was found to correlate with increasing multiplicity of infection by the
chimeric vector, and further retrotransposition from newly integrated elements was not observed on pro-
longed culture. Therefore, this vector, which utilizes components of low immunogenic potential, represents a
novel two-stage gene delivery system capable of achieving high titers via the initial helper-dependent adeno-
virus stage and permanent transgene integration via the retrotransposition stage.
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OVERVIEW SUMMARY
A retrotransposition-competent LINE-1 element (RC-L1)
was inserted into a helper-dependent adenovirus (HDAd) to
generate a hybrid adenovirus–retrotransposon vector. The
hybrid vector could be amplified to high titer and was ca-
pable of efficiently infecting a variety of human cells as an
adenovirus. The RC-L1 within the hybrid vector then un-
derwent retrotransposition in target cells, resulting in sta-
ble integration of the linked transgene cassette. A linear in-
crease in retrotransposition frequency was observed when
cells were infected at increasing multiplicities of infection.
Thus, we have developed a novel hybrid vector that can
achieve efficient transduction via the HDAd stage and sta-
ble integration of transgenes via the RC-L1 stage.
INTRODUCTION
THE LACK OF AN OPTIMAL METHOD for direct gene transferand permanent transduction of tissues in vivo is a signifi-
cant impediment to the success of human gene therapy. In seek-
ing to achieve efficient gene transfer, a variety of viruses have
been adapted for use as gene delivery vectors, including retro-
virus, adenovirus, and adeno-associated virus. Of these, ade-
noviral vectors are capable of achieving high titers and have
been shown to efficiently infect many cell types in vivo by di-
rect injection. However, because the adenovirus life cycle is in-
herently episomal in nature, and lacks the machinery for effi-
cient integration into host chromosomes, adenoviral integration
events are rare (Harui et al., 1999), and transgene expression
is transient in duration. Moreover, the utility of adenovirus vec-
tors is further limited by cellular and humoral immune re-
sponses against the adenoviral gene products, which can be ex-
pressed at low levels in the transduced cells despite deletion of
the E1 regulatory region (Yang et al., 1996a,b; Kaplan et al.,
1997; Sparer et al., 1997).
As one approach to overcome these limitations, helper-de-
pendent adenoviral vector systems, which lack all the coding
sequences that could be toxic or immunogenic to the host (Mi-
tani et al., 1995; Kochanek et al., 1996; Scheidner et al., 1998),
have been developed. These modifications not only allow an
expanded cloning capacity with the ability to insert up to 38 kb
of foreign DNA into the vector, but also result in prolonged ex-
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pression of the transgene compared with standard E1-deleted
adenovirus vectors (Morral et al., 1998, 1999; Morsy et al.,
1998; Scheidner et al., 1998), presumably because host immune
responses against the vector are reduced. Nevertheless, it is un-
likely that the transferred genes would persist permanently.
Human retrotransposons (i.e., long interspersed nuclear ele-
ments; LINE-1s or L1s) also have the potential to serve as gene
delivery vectors. Retrotransposition-competent L1s (RC-L1s)
are 6.0 kb and contain a 59 untranslated region (59 UTR) har-
boring an internal promoter (Swergold, 1990; Minakami et al.,
1992), two nonoverlapping open reading frames (ORF 1 and
ORF 2), and a 39 UTR that ends in a polyadenylic acid tail.
ORF 1 encodes a 40-kDa nucleic acid-binding protein that dis-
plays nucleic acid chaperone activity in vitro (Holmes et al.,
1992; Hohjoh and Singer, 1996; Martin and Bushman, 2001).
ORF 2 encodes a protein with reverse transcriptase (RT) and
endonuclease (EN) activities (Feng et al., 1996). Transgene cas-
settes can be inserted into the 39 UTR of RC-L1s, and the re-
sultant constructs can retrotranspose from an extrachromoso-
mal self-replicating plasmid episome into genomic DNA at a
high frequency, resulting in stable integration of the transgene
(Moran et al., 1996). However, a rate-limiting step in further
developing L1s as an integrating vector system has been their
inefficient delivery to target cells.
Here we describe a novel hybrid vector, consisting of an RC-
L1 encoded by a helper-dependent adenovirus vector. After ini-
tial transduction of cultured human cells by the adenovirus car-
rier, expression of the L1 and its subsequent retrotransposition
result in stable integration of the transgene cassette. Thus, this
L1–adenovirus hybrid vector simultaneously overcomes the
problems of transient adenovirus-mediated transgene expres-
sion and low efficiency of retrotransposon vector delivery. It
represents a novel vector system that is capable of achieving




Human embryonic kidney (HEK) 293A cells (Quantum
Biotechnologies, Laval, Quebec, Canada); 293Cre4 cells, which
stably express the Cre recombinase (Chen et al., 1996) (Merck,
Rahway, NJ); HeLa human cervical carcinoma cells (American
Type Culture Collection [ATCC], Rockville, MD); and
CFBE41o2 immortalized human bronchial epithelial cells (gen-
erously provided by D. Gruenert, University of California at
San Francisco, San Francisco, CA) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum, penicillin–streptomycin (20 U/ml), and 0.4
mM L-glutamine (DMEM-complete). 293Cre4 cells were cul-
tured in the presence of G418 (400 mg/ml). Plasmid pSTK120,
which contains genomic hypoxanthine phosphoribotransferase
(HPRT) and cosmid C346 stuffer sequences flanked by adeno-
virus serotype 5 (Ad5) inverted terminal repeats and packaging
signal (Kochanek et al., 1996), was generously provided by S.
Kochanek (University of Cologne, Cologne, Germany). The
construction of plasmid pJM130, which contains the human
retrotransposon L1.3 (Dombroski et al., 1993) linked to a
neomycin resistance transgene cassette (L1.3mneoI), has been
described previously (Sassaman et al., 1997). Plasmids were
purified with Qiagen (Valencia, CA) Maxiprep columns ac-
cording the manufacturer instructions.
Construction of helper-dependent
adenovirus–retrotransposon hybrid vector
A cytomegalovirus (CMV)-driven green fluorescent protein
(GFP) marker gene cassette was inserted between BamHI sites
in plasmid pSTK120 to generate an intermediate helper-de-
pendent adenovirus construct, designated pSMK-GFP. A
ScaI–ApaI restriction fragment containing the CMV-driven
L1.3mneoI sequence was then excised from pJM130 (Sassaman
et al., 1997), and ligated into the pSMK-GFP backbone after
digestion with EcoRV and ApaI; this procedure also results in
removal of the unstable Alu repeats in the HPRT intron se-
quence (Sandig et al., 2000). The resultant plasmid, pSMK-
L1.3mneoI, thus contains a 14.7-kb helper-dependent adenovi-
rus (HDAd) vector construct that encodes two independent
cassettes, CMV-L1.3mneoI and CMV-GFP.
HDAd vector production.The helper virus AdLC8cluc, a re-
combinant Ad5 vector containing loxP sites flanking the pack-
aging signal, was used to propagate the helper-dependent vec-
tor in 293Cre4 cells (Chen et al., 1996). After transfection of
PmeI-linearized pSMK-L1.3mneoI, the resultant helper-depen-
dent virus HDAd-L1.3mneoI was propagated by serial passage
on 293Cre4 cells with addition of the AdLC8cluc helper virus
at each stage, and purified by double cesium chloride gradient
ultracentrifugation (Parks et al., 1996). Helper virus contami-
nation levels were determined by median tissue culture infec-
tive dose (TCID50) and plaque assays on 293A cells. The helper-
dependent adenovirus was titered (transducing units, TU/ml) by
flow cytometric analysis of GFP expression from cells infected
with limiting dilutions of purified vector.
Southern blot analysis of adenovirus DNA. Approximately 107
TU of HDAd-L1.3mneoI virion DNA was incubated with 200
ml of capsid digestion buffer (50 mM Tris-HCl [pH 8.0], 1.0 mM
EDTA [pH 8.0], 0.5% sodium dodecyl sulfate [SDS], and pro-
teinase K [1.0 mg/ml]) at 50°C for 1 hr (Fisher et al., 1996a).
Reactions were cooled to room temperature, extracted once with
an equal volume of phenol–chloroform–isoamyl alcohol
(25:24:1), and precipitated with ethanol, and the virion DNA was
resuspended in 10 mM Tris-HCl, 0.1 mM EDTA. Virion DNA
was digested with restriction enzymes BstZ1107I (New England
BioLabs, Beverly, MA), EcoRI (GIBCO, Rockville, MD), and
NotI (New England BioLabs), fractionated on a 0.7% agarose
gel, blotted, and probed with a 32P-labeled PmeI restriction frag-
ment from pSMK-L1.3mneoI (Decaprime II; Ambion, Austin,
TX). Southern blots were analyzed by autoradiography or by
PhosphorImager 840 (Molecular Dynamics, Sunnyvale, CA).
Retrotransposition assay
HeLa cells (3–5 3 105) were infected with serial dilutions of
HDAd-L1.3mneoI (multiplicities of infection [MOIs] of 1, 10,
and 100). On day 2 posttransduction, the infected HeLa cells were
trypsinized and counted by hemocytometer, and cell dilutions
were plated in duplicate for selection in DMEM-complete plus
G418 (600 mg/ml). Uninfected HeLa cells were plated in paral-
lel as a negative selection control. In addition, an aliquot of the
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cells from each MOI was analyzed for GFP expression by flow
cytometry at various time points. Medium was changed every
2–3 days with DMEM-complete plus G418 (600 mg/ml) for 14
days. The resultant G418-resistant (G418R) colonies were fixed
and stained with 0.4% Giemsa for visualization. In addition, in-
dividual G418R clones from each MOI were harvested before
fixation and expanded in DMEM-complete plus G418 (600
mg/ml), and genomic DNA was harvested by standard methods
(Maniatis et al., 1982). Retrotransposition frequency was deter-
mined as number of G418R colonies divided by number of GFP-
positive cells, and normalized to HDAd-L1.3mneoI copy num-
ber per cell as quantitated by PhosphorImager analysis.
Retrotransposition titer was determined as input adenovirus titer
multiplied by retrotransposition frequency.
PCR analysis for retrotransposition
Polymerase chain reaction (PCR) was performed on genomic
DNA from individual G418R colonies to determine whether
proper splicing of the neoR transgene had occurred during retro-
transposition. Each PCR was performed in a 50-ml volume con-
taining 10 U of Taq polymerase, 0.2 mM dNTPs, , 200 ng of
genomic DNA template, and 200 ng of primers 437S and 1808S,
which are specific for the neoR gene. PCR was performed on
a PTC-100 thermocycler (MJ Research, Waltham, MA), using
a cycling program of 94°C, 1 min (1 cycle); 94°C, 1 min; 64°C,
30 sec; 72°C, 1 min (30 cycles); and a final extension of 72°C
for 10 min. One-fifth of the reaction volume was loaded onto
a 1.25% agarose gel containing ethidium bromide.
Southern blot analysis of retrotransposition events
After adenoviral infection at increasing MOIs and G418 se-
lection, 20 mg of genomic DNA from individual G418R colonies
was digested with EcoRI and fractionated on a 0.8% agarose
gel containing ethidium bromide. The resolved DNA was trans-
ferred to a nylon membrane (Hybond-N1; Amersham, Arling-
ton Heights, IL) and hybridized with a 32P-labeled DNA probe
to the neoR gene (Decaprime II; Ambion). To determine the
copy number of HDAd-L1.3mneoI after transduction (Fig. 3A),
total genomic DNA was harvested 24 hr posttransduction with
serial MOIs, digested with ScaI, resolved on a 0.8% agarose
gel, and subjected to Southern blot analysis with a 32P-labeled
DNA probe to the GFP gene. The standard curve was gener-
ated by addition of pSMK-L1.3mneoI plasmid DNA equivalent
to 0.5 to 100 copies per cell (Park et al., 2000) to genomic DNA
from uninfected cells. Since the HDAd-L1.3mneoI vector ge-
nome contains two copies of the GFP marker gene, two molar
equivalents of pSMK-L1.3mneoI was added to the uninfected
genomic DNA to create the standard curve. Southern blots were
analyzed by autoradiography or with a PhosphorImager 840
(Molecular Dynamics).
RESULTS
Construction, propagation, and characterization 
of HDAd-L1.3mneoI hybrid vector
The basic structure of the L1–adenovirus hybrid vector con-
struct (pSMK-L1.3mneoI) is shown in Fig. 1A. In this con-
struct, a retrotransposon element (L1.3) linked to a neomycin
resistance (neoR) retrotransposition indicator transgene cassette
(mneoI) was inserted into a 14.7-kb helper-dependent adenovi-
rus construct. The neoR gene is inserted in the antisense orien-
tation with respect to L1.3 and is disrupted by an intron (IVS
2 of the g-globin gene), which is in the sense orientation (see
also Fig. 2A). The arrangement of this retrotransposon/trans-
gene construct (here designated L1.3mneoI) has been described
previously (Moran et al., 1996; Sassaman et al., 1997), and en-
sures that only transgene expression linked to authentic retro-
transposition events will be scored. A green fluorescent protein
(GFP) marker gene driven by a cytomegalovirus (CMV) pro-
moter is also contained within the backbone of the helper-de-
pendent vector. As expression of the GFP marker gene is un-
linked to the L1.3mneoI retroelement, it serves as an
independent marker of adenoviral transduction and allows con-
venient determination of the helper-dependent adenovirus titer
by flow cytometry. The only adenovirus-derived sequences con-
tained within the chimeric vector are the inverted terminal re-
peats (ITRs) and the packaging signal sequence (c), which are
required for its propagation (Kochanek et al., 1996; Morsy et
al., 1998).
To propagate the helper-dependent vector derived from
pSMK-L1.3mneoI, essential viral functions were provided in
trans by AdLC8cluc, an attenuated helper virus that contains
loxP sites flanking its packaging signal. Thus, when coampli-
fied in a human 293-derived cell line expressing the Cre re-
combinase (293Cre4) (Chen et al., 1996), the packaging signal
is efficiently deleted from the helper virus, which inhibits its
ability to propagate and thereby confers a growth advantage to
the helper-dependent vector (Parks et al., 1996). Purified
helper-dependent adenovirus preparations were obtained at
titers of 4.74 3 109 transducing units (TU)/ml, as determined
by flow cytometric analysis of GFP expression in human 293
and HeLa cells after transduction with serial dilutions of virus
(Table 1). Levels of contamination by residual helper virus were
less than 0.1% by TCID50 assays (data not shown).
To determine the genomic structure of the retrotransposon-
adenovirus hybrid vector, DNA was isolated from helper-de-
pendent virions purified by double cesium gradient ultracen-
trifugation and analyzed by Southern blot (Fig. 1B and C). The
results indicate that the helper-dependent adenovirus, desig-
nated HDAd-L1.3mneoI, consists of a concatemer of the orig-
inal 14.7-kb pSMK-L1.3mneoI vector construct (Fig. 1B). This
was not unexpected, since helper-dependent adenovirus vectors
with smaller genomes can be packaged if concatemerization of
the vector sequence occurs, resulting in a multimeric size that
is within the packageable size range of 27 to 38 kb (Parks and
Graham, 1997; Morsy et al., 1998). The restriction digest 
patterns from Southern blot analysis of adenovirus DNA are
consistent with the presence of only a single species of helper-
dependent adenovirus derived from “tail-to-tail” concatemer-
ization of the original hybrid vector construct (Fig. 1C).
Helper-dependent adenovirus stage of the 
hybrid vector mediates efficient but transient
transduction of human cells
The HDAd-L1.3mneoI helper-dependent adenovirus is able
to infect a number of different human cell lines, including 293A,
HeLa, and CFBE41o2. Infections were initially performed at
low multiplicities of infection (MOI of , 1) to ensure that pre-
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FIG. 1. (A) Hybrid vector construct pSMK-L1.3mneoI. The sequences composing pSMK-L1.3mneoI are, from left to right,
the 59 inverted terminal repeat (ITR) of Ad5 (nt 1–440) including the packaging signal (c); the CMV-L1.3mneoI cassette from
pJM130 (10,236 bp), a CMV-GFP marker cassette (1914 bp), C346 cosmid stuffer sequence (2038 bp, cross-hatched box) from
pSTK120, and the Ad5 39 ITR (117 bp). PmeI restriction sites (P) flanking the ITRs release the 14.7-kb hybrid vector construct
from the plasmid backbone before amplification in 293Cre4 cells. The organization of the CMV-L1.3mneoI retrotransposon el-
ement is shown in detail, and consists of a CMV promoter (vertically lined box), the 59 untranslated region (59), ORF 1 product
P40, ORF 2 product EN and RT, and the neoR transgene, which is cloned into the 39 untranslated region of L1.3 in the reverse
orientation (oen) and flanked by SV40 promoter and polyadenylation sequences (hatched rectangles), and is interrupted by a for-
ward-splicing intron (IVS). (B) The HDAd-L1.3mneoI helper-dependent adenovirus genome after virus rescue and amplification
is a 29.4-kb tail-to-tail concatemer of the pSMK-L1.3mneoI hybrid vector construct. The restriction sites depicted are as follows:
B, Bst1107I; E, EcoRI; N, NotI. (C) Southern blot of HDAd-L1.3mneoI virion DNA hybridized with a 32P-labeled 14.7-kb PmeI
fragment from pSMK-L1.3mneoI. The restriction digest patterns are consistent with a tail-to-tail concatemer. Lane B, Bst1107I
digest (7875-bp doublet band and 13,740-bp single band); lane E, EcoRI digest (5336-bp doublet band and 18,818-bp single
band); lane N, NotI digest (1904-bp doublet band and 25,682-bp single band); lane U, uncut HDAd-L1.3mneoI virion DNA (.23-
kb marker). l/HindIII ladder molecular weight values are depicted on the left. (D) The first-stage HDAd-L1.3mneoI adenovirus
shows efficient but transient expression. HeLa cells infected with HDAd-L1.3mneoI (MOI of , 1) and analyzed by flow cytom-
etry were 96.3% positive for GFP expression 24 hr posttransduction (inset: uninfected negative control cells are represented as
the dark shaded area). Infected and uninfected HeLa cells were then serially passaged, and GFP expression was again determined
on days 2, 5, 8, and 11 posttransduction.
dominantly single-copy infections would occur. Under these
conditions, GFP expression from HDAd-L1.3mneoI should fol-
low the transient kinetics of low-copy adenovirus transduction.
As expected, flow cytometric analysis of GFP expression in ad-
enovirus-infected HeLa cells demonstrated highly efficient
transduction initially (Fig. 1D, inset), with expression levels
progressively diminishing over a period of several days as the
cells were serially passaged (Fig. 1D, graph). Similar results
were obtained from the other human cell lines tested (data not
shown).
Retrotransposon delivered by the hybrid 
vector is functional
As described above, the neoR transgene cassette linked to the
L1.3 element serves as an indicator of retrotransposition. Thus,
G418 resistance will arise only if L1.3 is transcribed from
HDAd-L1.3mneoI, the intron disrupting the neoR coding se-
quence is spliced out of the mRNA, and the mRNA is subse-
quently reverse transcribed and integrated into genomic DNA.
The now intact neoR gene can then be expressed from the simian
virus 40 (SV40) promoter (Moran et al., 1996; Sassaman et al.,
1997) (see Fig. 2A for details). Only true retrotransposition
events are scored in this assay, as mRNAs originating directly
from the SV40 promoter in the original helper-dependent ade-
novirus cannot be spliced, and therefore an intact neoR gene
product will not be produced. Consequently, even if rare ade-
noviral integration events were to occur, the cells would remain
G418 sensitive unless a true retrotransposition/integration event
occurred in the same cell.
The splicing required for reconstitution of the neoR trans-
gene provides a convenient assay for the presence of authentic
retrotransposition events, resulting in permanent integration
into the target cell genome. Accordingly, HeLa cells were in-
fected at increasing MOIs of HDAd-L1.3mneoI, the infected
cells were placed in G418 selection 48 hr posttransduction, and
selection was continued for 14 days. These G418-selected cells
no longer exhibited GFP fluorescence, suggesting that the 
adenovirus episome had already been eliminated. Genomic
DNA was isolated from more than 20 individual G418-resis-
tant clones that had been expanded, and PCR analysis was per-
formed to determine whether proper splicing of the intron had
occurred before reverse transcription and genomic integration.
Only the appropriately spliced PCR product was detected after
amplification of genomic DNA from all (.20) G418-resistant
colonies tested, regardless of the MOI used for initial infection
(Fig. 2B). We did not detect the larger unspliced PCR product
that would indicate the presence of the original adenovirus vec-
tor. Thus the G418-resistant phenotype was indeed the result
of authentic L1.3mneoI retrotransposition events originating
from the retrotransposon-adenovirus hybrid vector.
Genomic Southern blot analysis of retrotransposon-
mediated transgene integration events
To further confirm that the neoR transgene did integrate into
the genomic DNA and to examine the pattern of integration,
we performed Southern blot analysis of genomic DNA isolated
from G418-resistant HeLa clones that had been initially trans-
duced at increasing MOIs. These genomic DNA samples were
digested with EcoRI, which cuts only once within L1.3mneoI,
and hybridized with a radiolabeled neoR probe (Fig. 2A). These
clones were each originally derived from independent G418-
resistant colonies originating from different plates within the
same experiment or different experiments. Figure 3A shows
Southern blot results from a representative set of G418-resis-
tant HeLa clones. Only one major restriction fragment was de-
tected by the neoR probe in the majority of G418-resistant
clones examined, regardless of the initial MOI (Fig. 3A: MOI
of 1, 1A–1D; MOI of 10, 10A–10D; MOI of 100, 100A–100D).
The fragment sizes ranged from , 2.5 to .12 kb, suggesting
the L1.3mneoI element had integrated into random genomic lo-
cations. Multiple integration signals were observed in only 1 of
more than 20 independent clones examined, which had origi-
nally been transduced at an MOI of 100 (data not shown). Thus,
although initial adenovirus-mediated delivery of up to 100
copies of the L1.3mneoI retroelement per cell correlates with
an increase in the retrotransposition frequency in the overall
population, it appears that generally only single-copy integra-
tion events occurred within each cell. Dose-dependent cytoxi-
city was observed at MOIs greater than 100, preventing analy-
sis of multiple integration events at high copy numbers.
Previously integrated retrotransposon–transgene
elements are not mobilized with prolonged culture
To determine whether additional retrotransposition events
would occur over time from the initially integrated L1.3/neo
retroelements, three G418-resistant HeLa clones were serially
passaged an additional seven times (passages 1–8) under G418
selection over a period of 4 weeks, and genomic DNA from
passage 8 clones were isolated for Southern blot analysis as de-
scribed above. In all three G418R clones analyzed, the same
size fragment was detected in both passage 1 and passage 8, in-
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TABLE 1. DETERMINATION OF RETROTRANSPOSITION FREQUENCIES AND TITERSa
HDAd-L1.3 mneo Input HDAd-L1.3 mneo titer Retrotransposition Retrotransposition titer
MOI (copies/cell) (TU/ml) frequency (IU/ml)
1 00.8 4.74 3 109 1 ; 14,286 3.33 (6 0.6) 3 105
10 06 4.74 3 109 1 ; 1,3820 3.42 (6 0.4) 3 106
100 65.0 4.74 3 109 1 ; 28300 1.68 (6 0.05) 3 107
Abbreviations: MOI, Multiplicity of infection; TU/ml, transducing units per milliliter; IU/ml, integrating units per milliliter.
aThe retrotransposition frequency was normalized to 1, 10, and 100 copies of HDAd-L1.3 mneoI per cell as determined by
PhosphorImager analysis. The retrotransposition titer for each MOI was determined as (input HDAd-L1.3 mneoI titer) 3
(normalized retrotransposition frequency); see text for details.
dicating that integrated transgene is stable (Fig. 3B). Moreover,
no new hybridization signals were detected in the passage 8
clones, suggesting that additional retrotransposition events had
not occurred even with prolonged serial passage after initial in-
tegration of the L1.3mneoI element.
Quantification of integrating titers from the
retrotransposon stage of the hybrid vector
To accurately quantify the efficiency of retrotransposition af-
ter adenovirus-mediated delivery of the L1.3mneoI element, we
first sought to correlate the functional measure of adenovirus
transducing units at various MOIs with the physical copy num-
ber of introduced adenoviral genomes. Southern blots of total
genomic DNA from HeLa cells freshly infected at MOIs of 1,
10, and 100 were probed for the presence of the HDAd-
L1.3mneoI helper-dependent adenovirus genome, and the in-
tensity of the signal at each MOI was compared with a stan-
dard curve of increasing physical copy numbers (Fig. 4A).
PhosphorImaging demonstrated a good correlation between
functional MOIs and physical copy number, with infection at
an MOI of 1 resulting in approximately 0.8 copy of HDAd-
L1.3mneoI per cell, an MOI of 10 resulting in approximately
6 copies per cell, and an MOI of 100 resulting in approximately
65 copies per cell. Thus, increasing the MOI results in the de-
livery of correspondingly more copies of the retroelement to
each adenovirus-infected cell.
We next determined whether delivery of increasing numbers
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FIG. 2. (A) Overview of the L1.3mneoI retrotransposition assay. The CMV promoter drives transcription of L1.3mneoI, but
the neoR gene is in the antisense orientation and disrupted by an intron (IVS) in the sense orientation. Thus, a functional neoR
gene product will not be obtained unless the IVS is spliced out of the RNA transcript, followed by reverse transcription and in-
tegration of the intact neoR transgene. Subsequent expression of the neoR gene product from its own promoter (P9) ensures that
G418 resistance is conferred only to cells that have undergone authentic L1-mediated retrotransposition. The neoR gene probe
used for Southern blot analysis to examine the integration events occurring after retrotransposition from HDAd-L1.3mneoI was
generated by [32P]dCTP random priming of a 460-bp neoR gene fragment, and is indicated by the bar. The single EcoRI site [(E)]
present in L1.3 and the putative EcoRI site in genomic DNA [(E)] are also represented. (B) PCR assay for correct splicing of
the artificial intron in the neoR gene after retrotransposition from the HDAd-L1.3mneoI hybrid vector. The schematic at left il-
lustrates the unspliced product size and the correctly spliced product size after PCR amplification with neoR-specific primers.
Genomic DNA from individual G418R clones was used as the template for PCR. A representative set of PCR results from six
individual G418R clones is shown. Lane M, 1-kb molecular mass size ladder (GIBCO); lane -T, minus template control; lane U,
negative control genomic DNA from uninfected HeLa cells. The correct 486-bp PCR product (arrow), diagnostic of loss of the
intron, was detected in each clone (lanes 1A–100B; numbers denote MOI, letters denote individual clones). Lane V, 1361-bp un-
spliced product from HDAd-L1.3mneoI.
of the helper-dependent adenovirus stage of the hybrid vector
results in higher frequencies of retrotransposition and transgene
integration. HeLa cells infected with increasing MOIs of
HDAd-L1.3mneoI were analyzed by fluorescence-activated cell
sorting (FACS) 48 hr posttransduction to determine the num-
ber of adenovirus-transduced GFP-positive cells, and placed in
G418 selection for 14 days. Once selection was complete, the
number of G418-resistant colonies was counted to determine
the frequency of retrotransposon integration events. The results
of a representative experiment are shown in Fig. 4B, and dem-
onstrate that the second-stage retrotransposon component of the
hybrid vector is functional in conferring stable G418 resistance
to infected cells. Furthermore, delivering more copies of the
L1.3mneoI retroelement per cell by increasing the input MOI
results in an increased retrotransposition frequency.
Using as a denominator the number of cells initially trans-
duced by the first-stage HDAd-L1.3mneoI hybrid vector (de-
termined by flow cytometric analysis of GFP expression), the
frequency of the G418R phenotype was 1 in 14,286 cells con-
taining 1 copy of HDAd-L1.3mneoI. With 10-fold increases in
virion copy number, the retrotransposition frequency increased
to 1 event per 1382 transduced cells at 10 copies, and 1 event
per 283 cells at 100 copies of HDAd-L1.3mneoI (Table 1). On
the basis of the initial input titer of 4.74 3 109 transducing units
(TU)/ml for the first-stage HDAd-L1.3mneoI adenovirus, the
titer of retrotransposition/integration of the second-stage
L1.3mneoI element therefore corresponds to 3.33 3 105 inte-
grating units (IU) at 1 copy of HDAdL1.3neoI per cell, 3.42 3
106 IU at 10 copies per cell, and 1.68 3 107 IU at 100 copies
per cell (Fig. 4C and Table 1).
Time course of retrotransposition events after helper-
dependent adenovirus-mediated delivery of L1.3mneo
To determine whether L1 retrotransposition continues to oc-
cur as long as the first-stage adenovirus episome persists in the
infected cells, we examined the time course of retrotransposi-
tion events after initial transduction. To prolong expression
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FIG. 3. (A) Transduction of HeLa cells with HDAd-L1.3mneoI results in stable integration of the neoR transgene. Approxi-
mately 20 mg of genomic DNA from 12 individual clones (MOI of 1, lanes 1A–1D; MOI of 10, lanes 10A–10D; MOI of 100,
lanes 100A–100D) was digested with EcoRI and analyzed by Southern blot, using the neoR probe (Fig. 2A). Only one major re-
striction fragment of varying size is observed in each clone, indicating single retrotransposition/integration events had occurred.
Lane U, genomic DNA from untransduced negative control HeLa cells. l/HindIII ladder molecular weight values are depicted
at left. (B) Integrated L1.3mneoI elements are stable. Three stable G418R clones were passaged an additional seven times under
G418 selection (passage 1 and passage 8). Genomic DNA was collected at passage 1 and passage 8, digested with EcoRI and
analyzed by Southern blot, using a neoR probe (Fig. 2A). The same size fragment hybridized to the probe in both passage 1 and
passage 8 genomic DNA samples and no additional hybridization signals were detected in passage 8 genomic DNA. l/HindIII
ladder molecular weight values are depicted at left.
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FIG. 4. (A) Transduction with increasing MOIs correlates with delivery of increasing copy numbers of the HDAd-L1.3mneoI
hybrid vector. Total genomic DNA was harvested from HeLa cells 24 hr posttransduction with increasing MOIs of HDAd-
L1.3mneoI, digested with ScaI, and subjected to Southern blot analysis with a 32P-labeled GFP fragment (right). The actual copy
numbers of HDAd-L1.3mneoI delivered per cell at each MOI was determined by PhosphorImager analysis and comparison against
a standard curve. The standard curve was generated by addition of plasmid DNA corresponding to the indicated copy numbers
per cell to uninfected genomic DNA (left). (B) G418-resistant colonies generated from a representative retrotransposition assay.
HeLa cells were infected with serial dilutions of HDAd-L1.3mneoI (MOIs of 10 and 100) and placed in G418-selection 48 hr
posttransduction. Uninfected cells were selected in parallel as the negative control. G418 selection continued for 14 days, at which
point the resistant colonies were fixed and stained with 0.4% Giemsa for visualization. (C) Higher copy numbers of HDAd-
L1.3mneoI result in more efficient retrotransposition. The retrotransposition titer for each MOI was determined on the basis of
the initial input adenovirus titer (4.74 3 109 TU/ml) and the retrotransposition frequency observed at each MOI, adjusted for the
normalized copy number. *p , 0.05; **p , 0.01.
from the hybrid vector, we initially infected HeLa cells at MOIs
of 10 and 100. At these higher MOIs, GFP expression from the
first-stage adenovirus backbone persisted over a period of more
than 8 days (Fig. 5A) in the absence of G418 selection.
We then determined L1 retrotransposition frequencies at var-
ious time points after initial transduction by HDAd-L1.3mneoI
at MOIs of 10 and 100. The earliest time point assayed was on
day 2 posttransduction, at which point the cells were counted and
a defined number of transduced cells were placed in G418 se-
lection for 14 days. This assay therefore measures the cumula-
tive retrotransposition events occurring over a period of approx-
imately 10 days, including the 8-day lag period before initiation
of G418-mediated cell death plus the 2 days between transduc-
tion and the initiation of G418 selection. The remaining cells
were maintained without selection until the next time point. In
the absence of G418 selection, the frequency of cells harboring
early retrotransposition events should be maintained at a constant
level relative to cells in which no retrotransposition has yet oc-
curred (assuming both cell populations continue to divide at the
same rate), unless the continued presence of HDAd-L1.3mneoI
results in the accumulation of more cells that have newly inte-
grated the neoR transgene. Therefore, additional aliquots from the
originally transduced population maintained without selection,
consisting of the same number of transduced cells each time,
were similarly placed in G418 on day 5 and day 8 posttransduc-
tion and their retrotransposition frequencies were compared.
Interestingly, no increase in the retrotransposition frequency
was noted with this assay when G418 selection was initiated
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FIG. 5. (A) Transduction at high MOIs results in prolonged expression from the HDAd-L1.3mneoI adenovirus episome. HeLa
cells, transduced at MOIs of 10 and 100, were serially passaged and analyzed by flow cytometry for GFP expression on days 2,
5, and 8. More than 80% of cells continued to express GFP on day 8. (B) Retrotransposition frequency does not increase over
time despite continued expression from the HDAd-L1.3mneoI episome. Subsets of HeLa cells were placed into G418 selection
on days 2, 5, and 8 after transduction of the initial population at MOIs of 10 and 100. G418 selection was continued for 14 days,
at which point the resistant colonies were fixed and stained with 0.4% Giemsa as described above. The number of G418R colonies
obtained was normalized to 106 GFP-positive HeLa cells.
on days 2, 5, and 8 after the initial adenovirus infection (Fig.
5B). Thus, significant levels of additional retrotransposition do
not appear to occur despite prolonged expression from the hy-
brid vector over the time course examined. This suggests that
the majority of retrotransposition from the hybrid vector is a
relatively early event occurring within the first 10 days after
transduction.
DISCUSSION
To effect the stable integration or episomal persistence of
transgenes delivered via adenovirus vectors, a number of groups
have reported the development of hybrid vector systems that
contain retrovirus, adeno-associated virus (AAV), or Ep-
stein–Barr virus (EBV)-derived elements within the context of
standard E1-deleted or gutted adenovirus vectors (Fisher et al.,
1996; Bilbao et al., 1997; Yoshida et al., 1997; Caplen et al.,
1999; Recchia et al., 1999; Tan et al., 1999; Leblois et al., 2000;
Ueno et al., 2000). In the present paper we describe the devel-
opment of a unique retrotransposon–adenovirus chimeric vec-
tor system. Although use of retrotransposons as gene delivery
vehicles has been previously suggested (Kingsman et al., 1995;
Hodgson et al., 1997), and in fact retrotransposons such as rat
VL30 elements have been found capable of being packaged and
transmitted by murine leukemia virus (MLV) (Chakraborty et
al., 1994; Torrent et al., 1994), the efficiency of delivering
retrotransposon-encoded sequences to target cells has been the
rate-limiting step. Moreover, while adenovirus-mediated deliv-
ery of a horn fly DNA transposase has been reported (Zhang et
al., 1998), actual transposition events after adenovirus infection
of target cells were not demonstrated. Here we report the de-
velopment of a novel hybrid vector that could achieve efficient
delivery of a human retrotransposon in the context of a helper-
dependent adenovirus, ultimately resulting in stable integration
of a functional neomycin resistance transgene cassette. We fur-
ther found that increasing virion copy number resulted in in-
creased retrotransposition/integration titers that are comparable
to the stable transduction titers achieved by other integrating
vectors such as retroviruses.
In the present study we employed a retrotransposon vector
derived from a human L1 element. These non-long terminal re-
peat (LTR) elements are among the most well-characterized hu-
man retrotransposons, and are present in approximately
.500,000 copies in the human genome, although more than
99% of these are functionally inactive because of truncations
and rearrangements, and of the remaining 3000 or so full-length
L1 elements (Kazazian and Moran, 1998), it has been estimated
that only about 1.5–2.5% (i.e., 30 to 60 copies) are active in
retrotransposition (Sassaman et al., 1997).
The retrotransposition frequency we observed from the
HDAd-L1.3mneoI hybrid vector is in good concordance with
that previously reported for this element from plasmid trans-
fection studies. The specific L1 clone used in these studies, L1.3
(Dombroski et al., 1993), has previously been reported to retro-
transpose at a frequency of about 1 retrotransposition event
scored per 150 cells (Sassaman et al., 1997) when transfected
into cells in the context of a self-replicating EBNA/oriP plas-
mid system (Moran et al., 1996, 1999), which is maintained as
an episome at 10 to 100 copies per cell (Yates et al., 1985). In
addition, our observed retrotransposition frequency is consis-
tent with that reported for L1.3 linked to a GFP transgene (Os-
tertag et al., 2000), suggesting that the retrotransposition fre-
quency is an intrinsic characteristic of the L1 element and not
biased for G418 selection. With increasing MOI, we observed
a linearly correlated increase in the frequency of retrotranspo-
sition; at 100 copies of HDAd-L1.3mneoI per cell, the retro-
transposition frequency of L1.3mneoI was 1 retrotransposition
event per 283 adenovirus-infected cells. Furthermore, this study
represents the first use of an adenovirus-based hybrid vector
system to achieve titratable delivery of a retrotransposon, al-
lowing us to determine the inherent retrotransposition frequency
for a single copy of the L1.3mneoI element as approximately
1 in 14,000 cells.
On the basis of the first-stage HDAd-L1.3mneoI adenovirus
input titer of 4.74 3 109 TU/ml, the second-stage L1.3mneoI
retrotransposition/integration titer was therefore calculated to
be on the order of 3.33 3 105 IU at a physical copy number of
1 hybrid vector per cell. At higher MOIs, the integrating titer
reached as high as 1.68 3 107 IU. Thus, even in its present form
the stable transduction efficiency of this hybrid vector still com-
pares favorably with those of other integrating vectors such as
retroviruses. Furthermore, a new L1 element, L1RP, has been
discovered (Kimberland et al., 1999), which shows the highest
retrotransposition frequency (up to 1 event per 30 cells) ob-
served to date. Employing such elements in future generations
of retrotransposon–adenovirus hybrids will enhance the effi-
ciency of this vector system.
Only single integration events were observed in the majority
of subclones examined, even when HDAd-L1.3mneoI infections
were performed at a high MOI. This suggests that multiple retro-
transposition events do not occur frequently even when multiple
copies of the L1.3mneoI element are introduced into the target
cells, using a nonreplicating vector. The low abundance of clones
with multiple integration events (1:20 clones) is in contrast to an-
other report, which demonstrated that HeLa cells can accommo-
date multiple L1 insertions after plasmid transfection (Wei et al.,
2000). However, this latter result may be due to a quantitative
difference in the number of retrotransposon copies transiently in-
troduced into target cells at the time of chemical transfection,
which would be far greater than the approximately 65 copies in-
troduced by HDAd-L1.3mneoI even at an MOI of 100.
That the initial copy number is of primary importance in de-
termining the overall retrotransposition frequency is also sup-
ported by our observation that the majority of retrotransposi-
tion appears to occur within a relatively early time period after
hybrid vector-mediated introduction of the L1 element. Al-
though we did not detect an increasing retrotransposition rate
with longer expression of the retroelement after HDAd-
L1.3mneoI-mediated transduction, it has been demonstrated
that the L1.3 element can continue to retrotranspose at a rate
of about 0.1% of transfected cells per day when expressed from
a self-replicating plasmid (Ostertag et al., 2000) in hygromycin-
selected cells. In the latter study, the GFP-based indicator cas-
sette employed in the transfection studies might make possible
the more sensitive detection of additional retrotransposition in
stably selected cells; moreover, there was no selection for the
HDAd-L1.3mneoI adenovirus in our experiments.
We further observed that, while HDAd-L1.3mneoI-mediated
transduction was capable of giving rise to G418 resistance, ad-
ditional retrotransposition events did not occur from L1.3mneoI
elements that had already integrated, even on prolonged serial
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passage of the transduced cells. This result is consistent with
previous analyses of integrated L1/reporter elements, which
demonstrated a high frequency of truncated ORF 1 and ORF 2
sequences at their 59 ends, possibly because of the low proces-
sivity of the L1-encoded reverse transcriptase (RT) (Moran et
al., 1996; Kazazian and Moran, 1998). The propensity toward
truncations at the 59 end of L1 element is actually an advan-
tage for an L1-hybrid vector for gene delivery because it pro-
vides a built-in safety mechanism that greatly diminishes the
possibility of additional rounds of retrotransposition occurring
from previously integrated L1/transgene elements. Further-
more, one study demonstrated that heterologous L1 and cellu-
lar RNAs are mobilized at much lower frequences (,1%) when
compared with tagged, wild-type L1 clones, using a transfec-
tion system. Thus, in contrast to mariner-like DNA trans-
posases, L1-encoded proteins demonstrate a profound cis pref-
erence for their encoding RNA (Wei et al., 2001), so that
expression of L1 ORF products in human cells per se will not
lead to rampant trans-activation of endogenous L1 elements.
This cis preference further suggests that L1-based gene deliv-
ery systems will be relatively safe, and there is likely to be lit-
tle chance of promiscuous recurrent L1 retrotransposition lead-
ing to unacceptable frequencies of insertional mutagenesis.
One distinct advantage of this retrotransposon-adenovirus hy-
brid vector system is that the same cell that was originally trans-
duced by the first-stage adenovirus vector will itself be perma-
nently transduced by the second-stage L1 retrotransposon vector.
In contrast, retrovirus–adenovirus hybrid vector systems that
have been previously described require the initially transduced
cell to serve as a packaging intermediate for generation of the
second-stage retroviruses, which must then go forth to perma-
nently transduce adjacent cells (Bilbao et al., 1997; Caplen et
al., 1999). Another potential advantage of this retrotranspo-
son–adenovirus hybrid vector system is that L1 elements are
normally present endogenously in all human cells, making a cel-
lular immune response directed against the second-stage L1
retrotransposon components less likely to occur. In addition, as
the helper-dependent adenovirus vector used to deliver the L1
element is itself deleted of all the adenoviral genes, the first-
stage adenovirus carrier will be less toxic as well (Morral et al.,
1998, 1999). Therefore this type of retrotransposon-adenovirus
hybrid vector may provide a high-titer adenovirus-based system
that is potentially less immunogenic, yet capable of mediating
stable integration and permanent transduction of target cells.
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